Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The “HIV Treatment as Prevention” Experience in a Canadian Setting

There has been renewed call for the global expansion of highly active antiretroviral therapy (HAART) under the framework of HIV treatment as prevention (TasP). However, population-level sustainability of this strategy has not been characterized. We used population-level longitudinal data from provin...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 2; p. e87872
Main Authors Montaner, Julio S.G., Lima, Viviane D., Harrigan, P. Richard, Lourenço, Lillian, Yip, Benita, Nosyk, Bohdan, Wood, Evan, Kerr, Thomas, Shannon, Kate, Moore, David, Hogg, Robert S., Barrios, Rolando, Gilbert, Mark, Krajden, Mel, Gustafson, Reka, Daly, Patricia, Kendall, Perry
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 12.02.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text
ISSN1932-6203
1932-6203
DOI10.1371/journal.pone.0087872

Cover

More Information
Summary:There has been renewed call for the global expansion of highly active antiretroviral therapy (HAART) under the framework of HIV treatment as prevention (TasP). However, population-level sustainability of this strategy has not been characterized. We used population-level longitudinal data from province-wide registries including plasma viral load, CD4 count, drug resistance, HAART use, HIV diagnoses, AIDS incidence, and HIV-related mortality. We fitted two Poisson regression models over the study period, to relate estimated HIV incidence and the number of individuals on HAART and the percentage of virologically suppressed individuals. HAART coverage, median pre-HAART CD4 count, and HAART adherence increased over time and were associated with increasing virological suppression and decreasing drug resistance. AIDS incidence decreased from 6.9 to 1.4 per 100,000 population (80% decrease, p = 0.0330) and HIV-related mortality decreased from 6.5 to 1.3 per 100,000 population (80% decrease, p = 0.0115). New HIV diagnoses declined from 702 to 238 cases (66% decrease; p = 0.0004) with a consequent estimated decline in HIV incident cases from 632 to 368 cases per year (42% decrease; p = 0.0003). Finally, our models suggested that for each increase of 100 individuals on HAART, the estimated HIV incidence decreased 1.2% and for every 1% increase in the number of individuals suppressed on HAART, the estimated HIV incidence also decreased by 1%. Our results show that HAART expansion between 1996 and 2012 in BC was associated with a sustained and profound population-level decrease in morbidity, mortality and HIV transmission. Our findings support the long-term effectiveness and sustainability of HIV treatment as prevention within an adequately resourced environment with no financial barriers to diagnosis, medical care or antiretroviral drugs. The 2013 Consolidated World Health Organization Antiretroviral Therapy Guidelines offer a unique opportunity to further evaluate TasP in other settings, particularly within generalized epidemics, and resource-limited setting, as advocated by UNAIDS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: This study received limited unrestricted funding from Abbvie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare. The funding provided by the commercial sources has been directed to the institution and not to the investigators. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Conceived and designed the experiments: JSGM. Performed the experiments: JSGM VDL PRH LL BY BN EW TK KS DM RSH RB MG MK PD PK. Analyzed the data: JSGM VDL LL. Wrote the paper: JSGM VDL. Developed the first draft of the manuscript: JSGM VDL. Coordinated all edits thereafter, and contributed to the literature search of this manuscript: JSGM. Contributed to accessing and analyzing the data and approving the final version of the manuscript: VDL. Contributed to the preparation of document and collection of resistance data: PRH. Provided input on the scientific content of the manuscript: LL. Processed data, prepared datasets for analyses and edited the manuscript: BY. Reviewed and provided input on the scientific content of the manuscript: PRH LL BY BN EW TK KS DM RSH RB MK. Contributed to the interpretation of the incidence data and provided input on the scientific content of the manuscript: MG PD RG PK.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0087872